Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea Passes EU's GMP Equivalence Assessment For APIs

Executive Summary

The European Commission took four years to evaluate South Korea's regulatory framework for active pharmaceutical ingredients and to conclude that it is in line with EU standards.

You may also be interested in...



EU Explores New Ways To Boost Third-Country API Safety

The EU is working on new measures to ensure the safety of active substances imported from third countries, suggesting that the current system of requiring written notifications is not fit for purpose. The move follows recent cases of nitrosamine contamination in medicines containing imported APIs.

EU Looks At New Ways To Boost Third-Country API Safety

The EU is working on new measures to ensure the safety of active substances imported from third countries, suggesting that the current system of requiring written notifications is not fit for purpose. The move follows recent cases of nitrosamine contamination in medicines containing imported APIs.  

UK Brushes Up No-Deal Brexit Legislation

Some changes have been made to UK legislation that will aim to ensure the effective operation of the regulatory system once the country leaves the EU. Areas affected include the QPPV, pediatric and orphan medicines, and the reference product for generic approvals.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel